Compare Immunovant Inc. Common Stock (IMVT) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs NetApp Inc. — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B), while NetApp Inc. trades at $231.07 (market cap $45.38B). The key difference: NetApp Inc. is far larger — about 7.3× Immunovant Inc. Common Stock's market cap, and NetApp Inc. pays a 0.9% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and NetApp Inc. for 57 Days on average.
| IMVT | NTAP | |
|---|---|---|
Market Cap | $6.25B | $45.38B |
Volume | 1,755,411 | 2,264,311 |
Sector | Health | Technology |
52-Week High | $44.96 | $235.84 |
52-Week Low | $17.03 | $94.11 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $5.35B | $44.34B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NetApp (NTAP) trades at $235.84, up 3.23% today, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows bullish technical signals with support near $233 and resistance at $239. Fundamentals are robust with a 70.63% gross margin and 19.19% net income margin, though valuation multiples like the 33.3 P/E are elevated. Recent news highlights strategic AI partnerships and product launches, including Novus storage for AI infrastructure, driving positive sentiment.
Outlook is positive given earnings momentum and AI-driven growth, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is mixed with a $219.30 price target below current levels, suggesting caution despite bullish technicals. Institutional ownership trends and cash flow improvements support stability, but investors should weigh growth prospects against premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
